Prostate Cancer Clinical Trial
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Summary
The purpose of this study is to investigate the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer and to evaluate the effects of this treatment on the quality of life over time.
Full Description
In this study, CyberKnife radiosurgery will be used to produce dose distributions comparable to those created by High Dose Rate (HDR) brachytherapy treatment, without the use of invasive catheters. The radiosurgery volumes will closely be made to resemble HDR brachytherapy therapeutic volumes with similar dose limitation objectives to adjacent normal tissues.
The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The CyberKnife System delivers radiation using a precise targeting methodology allowing a focal treatment margin around the target, thus limiting the volume of adjacent tissue receiving high doses radiation. This in turn allows the delivery of high doses of radiation to the prostate over a short series of treatments.
Eligibility Criteria
Inclusion Criteria:
Patient must be at least 18 years of age
Histologically proven prostate adenocarcinoma
Biopsy within 1 year of date of registration
Clinical Stage (CS) T1b-T2b, N0, M0
Patients belonging to one of the following risk categories:
Low Risk: CS T1b-T2a, Gleason Score 2-6, Prostate Specific Antigen (PSA) < or = 10 ng/ml
Intermediate Risk: CS T2b, Gleason Score 2-6, PSA < or = 10 ng/ml or CS T1b-T2b, Gleason Score 2-6, PSA < or = 20 ng/ml or CS T1b-T2b, Gleason Score 7 and PSA < or = 10 ng/ml
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Exclusion Criteria:
Clinical Stage T2c or greater
Prior prostatectomy or cryotherapy of the prostate
Prior radiotherapy of the prostate or lower pelvis
Implanted hardware or other material that would prohibit appropriate treatment planning or delivery
History of an invasive malignancy other than basal or squamous skin cancers in the last 5 years
Hormone ablation for two months prior to enrollment or during treatment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 18 Locations for this study
Mobile Alabama, 36604, United States
Fresno California, 93721, United States
Long Beach California, 90806, United States
Pasadena California, 91105, United States
San Diego California, 92101, United States
Colorado Springs Colorado, 80907, United States
Lafayette Colorado, 80026, United States
Brandon Florida, 33511, United States
Lake Worth Florida, 33461, United States
Wellington Florida, 33449, United States
Elmhurst Illinois, 60126, United States
Great Falls Montana, 59405, United States
Las Vegas Nevada, 89128, United States
Egg Harbor Township New Jersey, 08234, United States
Chapel Hill North Carolina, 27599, United States
Oklahoma City Oklahoma, 73102, United States
Nashville Tennessee, 37203, United States
Tyler Texas, 75701, United States
How clear is this clinincal trial information?